No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...
The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...
Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...
Vertex Pharmaceuticals, a leader in Cystic Fibrosis ... with promising assets like Casgevy and Suzetrigine poised for future growth. Vertex's high valuation ratios suggest potential overvaluation ...
LONDON, August 07, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to ...
Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.
Naz Rahman, an analyst from Maxim Group, has initiated a new Hold rating on Vertex Pharmaceuticals (VRTX ... The launch of Casgevy for SCD and TDT is acknowledged as potentially blockbuster ...
The stock of Vertex Pharmaceuticals Incorporated VRTX has ... Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy Casgevy was approved for two blood disorders, sickle cell disease ...
Hosted on MSN1mon
Here's How to Play Vertex (VRTX) Stock After Q2 Loss, Price DipVertex Pharmaceuticals Incorporated VRTX reported ... Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy Casgevy was approved for two blood disorders, sickle cell disease ...
In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback